Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.

Autor: Lessans S; Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., O'Connell KA; Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA., Choe J; Department of Hematology/Oncology, Vanderbilt University Medical Center, Preston Research Building 790, 2220 Pierce Ave, Nashville, TN, 37232, USA. jennifer.choe@vumc.org.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2024 Sep; Vol. 26 (9), pp. 1120-1133. Date of Electronic Publication: 2024 Jul 02.
DOI: 10.1007/s11912-024-01570-1
Abstrakt: Purpose of Review: This review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma).
Recent Findings: Many studies demonstrate the effectiveness of immunotherapy for all types of non-melanoma skin cancer. For basal cell carcinoma (BCC), hedgehog inhibitors (HHI) remain first-line but with poor tolerability. Numerous clinical trials studying both neoadjuvant and adjuvant use of anti-PD-1 and anti-PD-L1 therapies in advanced NMSC are under investigation. There is a growing number of systemic therapies available to treat non-melanoma skin cancers. The advent of immunotherapy has revolutionized the field and greatly improved survival compared to historical survival rates with cytotoxic chemotherapy.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: